Cardiovascular disease in patients with psoriatic arthritis: correlation or causation?
Vol. 27 No. 1 (2019), Review articles
Vol. 27 No. 1 (2019)

Cardiovascular disease in patients with psoriatic arthritis: correlation or causation?

Review articles
https://doi.org/10.35465/27.1.2019.pp30-43
Published April 3, 2019
Alexander Krasimirov Angelov
Clinic of Rheumatology, University Hospital “St. Ivan Rilski”, Medical University - Sofia, Sofia, Bulgaria
Aleksandar Kopchev
Clinic of Rheumatology, University Hospital “St. Ivan Rilski”, Medical University - Sofia, Sofia, Bulgaria
Tsvetoslav Georgiev
Rheumatology department, Hospital “Serdika” – Sofia, Bulgaria
Mariana Ivanova
Clinic of Rheumatology, University Hospital “St. Ivan Rilski”, Medical University - Sofia, Sofia, Bulgaria
PDF BG/EN

Keywords

PsA
Psoriatic arthritis
CVD
Cardiovascular disease
Risk
Psoriasis
pathophysiology

How to Cite

Angelov, A., Kopchev, A., Georgiev, T., & Ivanova, M. (2019). Cardiovascular disease in patients with psoriatic arthritis: correlation or causation?. Rheumatology (Bulgaria), 27(1), 30-43. https://doi.org/10.35465/27.1.2019.pp30-43
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Psoriatic arthritis (PsA) is a pleiotropic inflammatory disease from the spectrum of spondyloarthritides which can potentially affect many organ systems. The chronic nature of the inflammatory milieu presented in rheumatic diseases, is similar to that of atherosclerosis, suggesting a common pathogenic basis. Effector cells of innate and adaptive immunity along with pro-inflammatory cytokines and other immune mediators may work together to potentiate endothelial damage and accelerate cardiovascular diseases (CVD). Thus, the risk of CVD and associated complications in PsA might be elevated, especially in patients with severe psoriasis, long-standing disease, and multiple comorbidities. This narrative review focuses on the prevalence of CVD in PsA patients, the overlapping molecular features in the pathogenesis of both conditions, and summarizes the benefits of the current treatments on impairments resolution.

https://doi.org/10.35465/27.1.2019.pp30-43
PDF BG/EN

References

  1. Ogdie, A., & Weiss, P. (2015). The Epidemiology of Psoriatic Arthritis. Rheumatic Diseases Clinics of North America, 41(4), 545–568. https://doi.org/10.1016/j.rdc.2015.07.001
  2. Ogdie, A., Schwartzman, S., & Husni, M. E. (2015). Recognizing and managing comorbidities in psoriatic arthritis. Current Opinion in Rheumatology, 27(2), 118–126. https://doi.org/10.1097/BOR.0000000000000152
  3. Takeshita, J., Grewal, S., Ead, S., Langan, M., Mehta, N. N., Ogdie, A., … Gelfand, J. M. (2017). Psoriasis and comorbid diseases Epidemiology. Journal of the American Academy of Dermatology, 76(3), 377–390. https://doi.org/10.1016/j.jaad.2016.07.064
  4. Van Doornum, S., McColl, G., & Wicks, I. P. (2002). Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis and Rheumatism, 46(4), 862–873. https://doi.org/10.1002/art.10089
  5. Ross, R. (1999). ATHEROSCLEROSIS — an Inflammatory Disease. The New England Journal of Medicine, 340(2), 115–126. https://doi.org/10.1056/NEJM199901143400207
  6. Agca, R., Heslinga, S. C., Van Halm, V. P., & Nurmohamed, M. T. (2016). Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart, 102(10), 790–795. https://doi.org/10.1136/heartjnl-2015-307838
  7. Ramonda, R., Lo Nigro, A., Modesti, V., Nalotto, L., Musacchio, E., Iaccarino, L., … Doria, A. (2011). Atherosclerosis in psoriatic arthritis. Autoimmunity Reviews, 10(12), 773–778. https://doi.org/10.1016/j.autrev.2011.05.022
  8. Jamnitski, A., Symmons, D., Peters, M. J. L., Sattar, N., MciInnes, I., & Nurmohamed, M. T. (2013). Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Annals of the Rheumatic Diseases, 72(2), 211–216. https://doi.org/10.1136/annrheumdis-2011-201194
  9. Puig, L. (2018). Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. International Journal of Molecular Sciences, 19(1). https://doi.org/10.3390/ijms19010058
  10. TOBIN, A.-M., VEALE, D. J., FITZGERALD, O., ROGERS, S., COLLINS, P., O’SHEA, D., & KIRBY, B. (2010). Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. The Journal of Rheumatology, 37(7), 1386–1394. https://doi.org/10.3899/jrheum.090822
  11. Edson-Heredia, E., Zhu, B., Lefevre, C., Wang, M., Barrett, A., Bushe, C. J., … Maeda-Chubachi, T. (2015). Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: A retrospective study using Clinical Practice Research Datalink. Journal of the European Academy of Dermatology and Venereology, 29(5), 955–963. https://doi.org/10.1111/jdv.12742
  12. Gladman, D. D., Ang, M., Su, L., Tom, B. D. M., Schentag, C. T., & Farewell, V. T. (2009). Cardiovascular morbidity in psoriatic arthritis. Annals of the Rheumatic Diseases, 68(7), 1131–1135. https://doi.org/10.1136/ard.2008.094839
  13. Ahlehoff, O., Gislason, G. H., Charlot, M., Jørgensen, C. H., Lindhardsen, J., Olesen, J. B., … Hansen, P. R. (2011). Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study. Journal of Internal Medicine, 270(2), 147–157. https://doi.org/10.1111/j.1365-2796.2010.02310.x
  14. Wu, C. Y., Hu, H. Y., Li, C. P., Chou, Y. J., & Chang, Y. T. (2018). Comorbidity profiles of psoriasis in Taiwan: A latent class analysis. PLoS ONE, 13(2), 1–10. https://doi.org/10.1371/journal.pone.0192537
  15. Shah, K., Paris, M., Mellars, L., Changolkar, A., & Mease, P. J. (2017). Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open, 3(2), e000588. https://doi.org/10.1136/rmdopen-2017-000588
  16. Gulati AM, Salvesen Ø, Thomsen RS, et al Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT) RMD Open 2018;4:e000630. doi: 10.1136/rmdopen-2017-000630
  17. Wibetoe, G., Ikdahl, E., Rollefstad, S., Olsen, I. C., Bergsmark, K., Kvien, T. K., … Semb, A. G. (2017). Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Research & Therapy, 19(1), 153. https://doi.org/10.1186/s13075-017-1358-1
  18. Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1510-1518. doi: 10.1002/acr.23171.
  19. Nissen, C. B., Hørslev-Petersen, K., & Primdahl, J. (2017). Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. Rheumatology International, 37(1), 113–120. https://doi.org/10.1007/s00296-016-3614-0
  20. Sinnathurai, P., Buchbinder, R., Hill, C., Lassere, M., & March, L. (2018). Comorbidity in psoriatic arthritis and rheumatoid arthritis. Internal Medicine Journal. https://doi.org/10.1111/imj.14046
  21. Horreau, C., Pouplard, C., Brenaut, E., Barnetche, T., Misery, L., Cribier, B., … Richard, M. A. (2013). Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review. Journal of the European Academy of Dermatology and Venereology, 27(SUPPL.3), 12–29. https://doi.org/10.1111/jdv.12163
  22. Egeberg, A., Thyssen, J. P., Jensen, P., Gislason, G. H., & Skov, L. (2017). Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: A nationwide cohort study. Acta Dermato-Venereologica, 97(7), 819–824. https://doi.org/10.2340/00015555-2657
  23. Van Raemdonck, K., Umar, S., Szekanecz, Z., Zomorrodi, R. K., & Shahrara, S. (2018). Impact of obesity on autoimmune arthritis and its cardiovascular complications. Autoimmunity Reviews, 17(8), 821–835. https://doi.org/10.1016/j.autrev.2018.02.007
  24. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014 Sep;13(9):981-1000. doi: 10.1016/j.autrev.2014.07.001.
  25. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40(2):199–205.
  26. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit. 2005;11(5):RA155–162.
  27. Yvan-Charvet L, Quignard-Boulangé A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. 2011 Jan;79(2):162-8. doi: 10.1038/ki.2010.391.
  28. Al Johani, R., Polachek, A., Ye, J. Y., Chandran, V., & Gladman, D. D. (2018). Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. Journal of Rheumatology, 45(2), 213–217. https://doi.org/10.3899/jrheum.170384
  29. Kuwabara, M. (2016). Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse, 3(3–4), 242–252. https://doi.org/10.1159/000443769
  30. EISEN AZ, SEEGMILLER JE. Uric acid metabolism in psoriasis. J Clin Invest. 1961;40(8 Pt 1-2):1486-94. doi: 10.1172/JCI104379
  31. Laura Billiet, Sarah Doaty, James D. Katz, and Manuel T. Velasquez, “Review of Hyperuricemia as New Marker for Metabolic Syndrome,” ISRN Rheumatology, vol. 2014, Article ID 852954, 7 pages, 2014. https://doi.org/10.1155/2014/852954.
  32. Tsuruta, N., Imafuku, S., & Narisawa, Y. (2017). Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. Journal of Dermatology, 44(12), 1349–1352. https://doi.org/10.1111/1346-8138.13968
  33. Zhen, H., & Gui, F. (2017). The role of hyperuricemia on vascular endothelium dysfunction. Biomedical Reports, 325–330. https://doi.org/10.3892/br.2017.966
  34. Arida, A., Protogerou, A. D., Kitas, G. D., & Sfikakis, P. P. (2018). Systemic inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases. International Journal of Molecular Sciences, 19(7), 1–27. https://doi.org/10.3390/ijms19071890
  35. Taleb, S., & Tedgui, A. (2018). IL-17 in atherosclerosis: the good and the bad. Cardiovascular Research, 114(1), 7–9. https://doi.org/10.1093/cvr/cvx225
  36. Garg N, Krishan P, Syngle A. Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function. Int J Angiol. 2016;25(4):222-228.
  37. Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O. Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity. Arthritis Rheumatol. 2018 Mar;70(3):396-407. doi: 10.1002/art.40389
  38. Di Minno MN, Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, Tremoli E. Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Ann Med. 2015 Jun;47(4):346-53. doi: 10.3109/07853890.2015.1031822.
  39. Gonzalez-Juanatey, C., Llorca, J., Miranda-Filloy, J. A., Amigo-Diaz, E., Testa, A., Garcia-Porrua, C., … Gonzalez-Gay, M. A. (2007). Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Care and Research, 57(2), 287–293. https://doi.org/10.1002/art.22530
  40. Apraş Bilgen, Ş. (2018). Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 46(5), 358–365. https://doi.org/10.5543/tkda.2018.36169
  41. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, Comaneshter D, Paran D, Wigler I, Levartovsky D, Berliner S, Elkayam O. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007 Feb;36(4):203-9
  42. Shang, Q., Tam, L.-S., Sanderson, J. E., Sun, J.-P., Li, E. K.-M., & Yu, C.-M. (2012). Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology, 51(12), 2215–2223. https://doi.org/10.1093/rheumatology/kes213
  43. Souza, C. S., de Castro, C. C. S., Carneiro, F. R. O., Pinto, J. M. N., Fabricio, L. H. Z., Azulay-Abulafia, L., … Oyafuso, L. K. M. (2018). Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence. The Journal of Dermatology, (March), 1–8. https://doi.org/10.1111/1346-8138.14706
  44. Temple NJ. Fat, Sugar, Whole Grains and Heart Disease: 50 Years of Confusion. Nutrients. 2018 Jan 4;10(1). pii: E39. doi: 10.3390/nu10010039. Review. PubMed PMID: 29300309; PubMed Central PMCID: PMC5793267.
  45. Ma, Y., Chiriboga, D. E., Olendzki, B. C., & Hebert, J. R. (2007). Association between Carbohydrate Intake and Serum Lipids, 25(2), 155–163. https://doi.org/10.1080/07315724.2006.10719527
  46. Reitsma, Sietze. "The endothelial glycocalyx: composition, functions, and visualization." European Journal of Physiology. 2007. Vol. 454. Num. 3. p. 345-359
  47. Dogné, S., Flamion, B., & Caron, N. (2018). Endothelial Glycocalyx as a Shield Against Diabetic Vascular ComplicationsHighlights. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(7), 1427–1439. https://doi.org/10.1161/ATVBAHA.118.310839
  48. Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, Conzen P, Becker BF. TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol. 2009 Jan;104(1):78-89. doi: 10.1007/s00395-008-0749-5.
  49. Devaraj S, Yun JM, Adamson G, Galvez J, Jialal I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res. 2009;84(3):479-84.
  50. Zeng Y. Endothelial Glycocalyx: Novel Insight into Atherosclerosis. J Biomed 2017; 2:109-116. doi:10.7150/jbm.17725.
  51. Nieuwdorp, M., Haeften, T. W. Van, Gouverneur, M. C. L. G., Mooij, H. L., Lieshout, M. H. P. Van, Levi, M., … Stroes, E. S. G. (2006). Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo. Diabetes, 55(February), 480–486.
  52. Lipowsky HH. Protease Activity and the Role of the Endothelial Glycocalyx in Inflammation. Drug Discov Today Dis Models. 2011 Spring;8(1):57-62.
  53. Olivieri, I., Padula, A., D’Angelo, S., & Scarpa, R. (2008). Role of trauma in psoriatic arthritis. Journal of Rheumatology, 35(11), 2085–2087. https://doi.org/10.1063/1.1457526
  54. Bansal SS, Ismahil MA, Goel M, Zhou G, Rokosh G, Hamid T, Prabhu SD. Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy. Circulation. 2019 Jan 8;139(2):206-221. doi: 10.1161/CIRCULATIONAHA.118.036065.
  55. Francesco Paolo Cantatore, Nicola Maruotti, Addolorata Corrado, and Domenico Ribatti, “Angiogenesis Dysregulation in Psoriatic Arthritis: Molecular Mechanisms,” BioMed Research International, vol. 2017, Article ID 5312813, 6 pages, 2017. https://doi.org/10.1155/2017/5312813.
  56. Bedoya SK, Lam B, Lau K, Larkin J. Th17 cells in immunity and autoimmunity. Clin Dev Immunol. 2013;2013:986789.
  57. Caiazzo, G., Fabbrocini, G., Di Caprio, R., Raimondo, A., Scala, E., Balato, N., & Balato, A. (2018). Psoriasis, cardiovascular events, and biologics: Lights and shadows. Frontiers in Immunology, 9(AUG). https://doi.org/10.3389/fimmu.2018.01668
  58. Soler DC, McCormick TS. The dark side of regulatory T cells in psoriasis. J Invest Dermatol. 2011;131(9):1785-6.
  59. Ezeonyeji A, Baldwin H, Vukmanovic-Stejic M, Ehrenstein MR. CD4 T-Cell Dysregulation in Psoriatic Arthritis Reveals a Regulatory Role for IL-22. Front Immunol. 2017;8:1403. Published 2017 Oct 27. doi:10.3389/fimmu.2017.01403
  60. Cicha, I., & Urschel, K. (2015). TNF-α in the cardiovascular system: from physiology to therapy. International Journal of Interferon, Cytokine and Mediator Research, 7, 9. https://doi.org/10.2147/IJICMR.S64894
  61. Buckley, L. F., & Abbate, A. (2018). Interleukin-1 blockade in cardiovascular diseases: A clinical update. European Heart Journal, 39(22), 2063–2069. https://doi.org/10.1093/eurheartj/ehy128
  62. Ogata A, Kumanogoh A, Tanaka T. Pathological role of interleukin-6 in psoriatic arthritis. Arthritis. 2012;2012:713618.
  63. Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol. 2018;9:754. Published 2018 Apr 13. doi:10.3389/fimmu.2018.00754
  64. Cozlea DL, Farcas DM, Nagy A, et al. The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J. 2013;39(4):225-31.
  65. Zhou, W., Chen, C., Chen, Z., Liu, L., Jiang, J., Wu, Z., … Chen, Y. (2018). NLRP3: A novel mediator in cardiovascular disease. Journal of Immunology Research, 2018. https://doi.org/10.1155/2018/5702103
  66. Su F, Xia Y, Huang M, Zhang L, Chen L. Expression of NLPR3 in Psoriasis Is Associated with Enhancement of Interleukin-1β and Caspase-1. Med Sci Monit. 2018;24:7909-7913. Published 2018 Nov 5. doi:10.12659/MSM.911347
  67. Kopchev, A., Monov, S., Kyurkchiev, D., Ivanova, I., & Georgiev, T. (2017). Vascular endothelial growth factor ( VEGF ), cartilage oligomeric protein ( COMP ) and matrix metalloproteinase 3 ( MMP-3 ) as serum biomarkers in psoriatic arthritis, 6(7), 8–12.
  68. Ramos MA, Kuzuya M, Esaki T, Miura S, Satake S, Asai T, Kanda S, Hayashi T, Iguchi A. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1188-96. PubMed PMID: 9672081.
  69. Mittal B, Mishra A, Srivastava A, Kumar S, Garg N. Matrix metalloproteinases in coronary artery disease. Adv Clin Chem. 2014;64:1-72. Review. PubMed MID: 24938016.
  70. Jensen, P., Wiell, C., Milting, K., Poggenborg, R. P., Østergaard, M., Johansen, J. S., & Skov, L. (2013). Plasma YKL-40: A potential biomarker for psoriatic arthritis? Journal of the European Academy of Dermatology and Venereology, 27(7), 815–819. https://doi.org/10.1111/j.1468-3083.2012.04570.x
  71. Rathcke, C. N., & Vestergaard, H. (2009). YKL-40 - an emerging biomarker in cardiovascular disease and diabetes. Cardiovascular Diabetology, 8, 1–7. https://doi.org/10.1186/1475-2840-8-61
  72. Ogdie, A., Yu, Y., Haynes, K., Love, T. J., Maliha, S., Jiang, Y., … Gelfand, J. M. (2015). Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 74(2), 326–332. https://doi.org/10.1136/annrheumdis-2014-205675
  73. Ahlehoff, O., Skov, L., Gislason, G., Lindhardsen, J., Kristensen, S. L., Iversen, L., … Hansen, P. R. (2013). Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: A Danish real-world cohort study. Journal of Internal Medicine, 273(2), 197–204. https://doi.org/10.1111/j.1365-2796.2012.02593.x
  74. Lee, J. L., Sinnathurai, P., Buchbinder, R., Hill, C., Lassere, M., & March, L. (2018). Arthritis Research & Therapy, 20(1), 171. https://doi.org/10.1186/s13075-018-1669-x
  75. Manolis, A. S., Manolis, T. A., Melita, H., Manolis, A. S., Manolis, A. S., Manolis, T. A., … Antonis, S. (2018). International Reviews of Immunology Psoriasis and cardiovascular disease : the elusive link. International Reviews of Immunology, 0(0), 1–22. https://doi.org/10.1080/08830185.2018.153908
  76. Agca, R., Heslinga, M., Kneepkens, E. L., van Dongen, C., & Nurmohamed, M. T. (2017). The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic Arthritis. The Journal of Rheumatology, 44(9), 1362–1368. https://doi.org/10.3899/jrheum.161418
  77. Garshick, M., & Underberg, J. A. (2017). The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Current Atherosclerosis Reports, 19(12). https://doi.org/10.1007/s11883-017-0685-7
  78. Thomsen, R. S., Nilsen, T. I. L., Haugeberg, G., Bye, A., Kavanaugh, A., & Hoff, M. (2018). Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: A randomised controlled trial. RMD Open, 4(2), 1–9. https://doi.org/10.1136/rmdopen-2018-000729
  79. Agca, R., Heslinga, S. C., Rollefstad, S., Heslinga, M., McInnes, I. B., Peters, M. J. L., … Nurmohamed, M. T. (2016). EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases, 76(1), 17–28. https://doi.org/10.1136/annrheumdis-2016-209775
  80. Koolaee, R. M., Takeshita, J., & Ogdie, A. (2013). Epidemiology and Natural History of Psoriatic Arthritis: an UpdateWhat Dermatologists Need to Know. Current Dermatology Reports, 2(1), 66–76. https://doi.org/10.1007/s13671-012-0032-8
  81. Johnsson, H., McInnes, I. B., & Sattar, N. (2012). Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. Annals of the Rheumatic Diseases, 71(4), 480–483. https://doi.org/10.1136/annrheumdis-2011-200567
  82. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, Park HS, Cho Y, Chae SC, Jun JE, Park WH. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J. 2006 Nov;70(11):1379-84
  83. Breunig, M., Kleinert, S., Lehmann, S., Kneitz, C., Feuchtenberger, M., Tony, H. P., … Störk, S. (2018). Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scandinavian Journal of Rheumatology, 47(2), 102–109. https://doi.org/10.1080/03009742.2017.1337924
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.